Alnylam Pharmaceuticals, Inc. (ALNY) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:00 PM EST
Company Participants
Yvonne Greenstreet – CEO & Director
Jeffrey Poulton – CFO & Executive VP
Tolga Tanguler – Executive VP & Chief Commercial Officer
Pushkal Garg – EVP of Development & Medical Affairs and Chief Research & Dev. Officer
Conference Call Participants
Jessica Fye – JPMorgan Chase & Co, Research Division
Presentation
Jessica Fye
JPMorgan Chase & Co, Research Division
Good morning, everyone. My name is Jess Fye, biotech analyst at JPMorgan, and we’re continuing the 44th Annual JPMorgan Healthcare Conference this morning with Alnylam. Company had a lot of updates yesterday. I’m sure we’ll talk about those.
We’re going to start out with a presentation from the company’s CEO, Yvonne Greenstreet, and then we’re going to go into some Q&A. [Operator Instructions] But with that, let me pass it over to Yvonne.
Yvonne Greenstreet
CEO & Director
Thank you, Jessica. Look, it’s a real pleasure to be standing here as we launch this next exciting chapter in Alnylam’s history. I’m Yvonne Greenstreet, the CEO of Alnylam, and I’m delighted to be joined on stage here — maybe stand back a bit — by my colleagues, Pushkal Garg, our Chief R&D Officer; Tolga Tanguler, our Chief Commercial Officer; and Jeff Poulton, our Chief Financial Officer. And of course, I’ll be making forward-looking statements throughout my presentation.
Now as most of you know, Alnylam possesses a unique profile in the biotech industry. And what makes us so unique is that we have an established and sustainable innovation engine, coupled with commercial excellence. This has fueled our success to date, and we will continue to harness this to drive durable long-term growth. And it all begins with the leadership that we’ve established in RNAi with a proven organic product engine and a reproducible and
